IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1797
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$4.1B
Dinesh V. Patel
Protagonist Therapeutics, Inc. discovers and develops peptide-based therapeutic drugs. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis. PN-943, an oral, alpha-4-beta-7 integrin-specific antagonist peptide, is in clinical trials.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$PTGX Protagonist Therapeutics, Inc | 51 | 38 | 47 | 75 | - | - | -18.4% | -17.0% | 100.0% | -674.5% | -553.3% | 13.1% | 0.0% | 9.0x | $4.1B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Protagonist Therapeutics, Inc (PTGX) receives a "Hold" rating with a composite score of 51.4/100. It ranks #1797 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Outperforming peers — winners tend to keep winning over 3-12 months
Fair valuation relative to peers
Average quality profile
Low volatility — smoother ride and historically better risk-adjusted returns
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for PTGX.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 38 | 26 | +12ALPHA |
| MOMENTUM | 75 | 80 | -5NEUTRAL |
| VALUATION | 47 | 37 | +10ALPHA |
| INVESTMENT | 49 | 90 | -41DRAG |
| STABILITY | 71 | 74 | -3NEUTRAL |
| SHORT INT | 29 | 19 | +10ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -18.4% (sector -1.9%)
GM 100% vs sector 44%, OM -675% vs sector 3%
Capital turnover N/A, R&D intensity 292.7%
Rev growth 13%, 10yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Protagonist Therapeutics, Inc (PTGX) as a Hold with a composite score of 51.4/100 at a current price of $87.36. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
Protagonist Therapeutics, Inc holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 51.4/100 places it at rank #1797 in our full universe.
The near-term outlook is constructive, with revenue growing at 13% and momentum in the 75th percentile confirming positive market sentiment. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy.
No Moat
Medium
Poor
Fair Value
Gross margins of 100% signal strong pricing power.
Positive momentum indicates institutional accumulation.
Stable competitive position in a defensive sector.
Vulnerability to macroeconomic shocks and interest rate volatility.
Protagonist Therapeutics, Inc represents a hold based on multi-factor quantitative performance.
Our model assigns Protagonist Therapeutics, Inc a Hold rating, with a composite score of 51.4/100 and 3 out of 5 stars. Ranked #1797 of 7,333 stocks, PTGX presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
PTGX's quality score of 38/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -18.4% (sector avg: -1.9%), gross margins of 100.0% (sector avg: 44.1%), net margins of -553.3% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 47/100, PTGX appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 8.02x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
With an investment score of 49/100, PTGX exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of 13.1% vs. a sector average of 6.7% and a return on assets of -17.0% (sector: 0.9%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
PTGX shows strong momentum characteristics with a score of 75/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth stands at 13.1% year-over-year, while a beta of -0.10 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
PTGX shows good financial stability with a score of 71/100. Key stability metrics include a beta of -0.10 and a debt-to-equity ratio of 9.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
Protagonist Therapeutics, Inc's short interest score of 29/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 9.00x). At $4.1B (mid-cap), PTGX carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Protagonist Therapeutics, Inc is a mid-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1797 of 7,333 overall (75th percentile). Key comparisons include ROE of -18.4% trailing the -1.9% sector median and operating margins of -674.5% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While PTGX currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Momentum (75) vs Short Int. (29) — closing this gap could shift the rating.
ROE 870% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 127% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 26973% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Douglas Lane & Associates increased its Johnson & Johnson stake by 34,948 shares, worth approximately $6 million in Q3, bringing total holdings to 667,373 shares valued at $123.7 million. The investment comes ahead of J&J's earnings report and potential biotech acquisition of Protagonist Therapeutics.
Protagonist Therapeutics submitted NDAs for Icotrokinra in plaque psoriasis and Rusfertide in polycythemia vera, advancing two late stage drug candidates. The company is progressing Phase 3 trials in partnership with large pharmaceutical companies, including Johnson & Johnson and Takeda. These filings and trial advances represent fresh milestones for NasdaqGM:PTGX that have not yet been widely discussed in the market. Protagonist Therapeutics, trading on NasdaqGM:PTGX, is drawing fresh...
We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy. On January 30, H.C. Wainwright raised its price target on Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to $117 from $80 and reiterated a Buy rating. The firm cited the company’s track record in drug development and assigned probability-of-success assumptions across multiple programs, including […]
As February begins, the U.S. stock market has shown a robust start with major indices like the Dow Jones and S&P 500 posting significant gains, reflecting positive sentiment despite recent economic uncertainties such as delayed jobs reports and trade policy shifts. In this dynamic environment, high growth tech stocks are often characterized by their innovative capabilities and potential to leverage emerging trends like AI and cloud computing, making them intriguing options for investors...
NEWARK, CA / ACCESS Newswire / February 24, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in multiple investment bank conferences ...